The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.Methods This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.Findings Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).Interpretation Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.Funding Bayer AG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A study shared that low-dose rivaroxaban with aspirin reduced major adverse cardiovascular and limb events compared with aspirin alone without significantly increasing major bleeding [82].”
From Revascularization Strategies for Acute and Chronic Mesenteric Ischemia: A Narrative Review (2024) · cites this paper as [82]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“a review of 56 studies including patients with diabetes suggested higher limbsalvage rates after revascularization (78-85% at 1 year) compared with conservative management.768”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [768]
In the citing paper
“The risk of major adverse cardiovascular events (MACEs) was significantly lower with the combination of rivaroxaban plus aspirin compared with either aspirin alone or rivaroxaban alone.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“The ischemic benefits of rivaroxaban were consistent in the subgroup with diabetes mellitus, suggesting that low-dose anticoagulation added to antiplatelet therapy may be another option for secondary prevention in patients with T2DM and stable CAD.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“There was an associated increased risk of bleeding with rivaroxaban, although no significant excess in fatal bleeding was noted.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationClopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Self-citationRivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Self-citationRivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J., Bhatt, D. L., Bode, C., Burton, P. B. J., Cohen, M. C., Cook‐Bruns, N., Fox, K. A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,923
Self-citationESC Guidelines on the diagnosis and treatment of peripheral artery diseases
Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr211 · Cited by 1,506
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationOne-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Self-citationGerhard‐Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,048
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820d8d78 · Cited by 801
Self-citationConnolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Self-citation
Research works printed but not linked: 2
- 1996, A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE), Lancet, 348, 329
- Connolly, 2017, Rivaroxaban in stable coronary disease, Lancet
Cited by
Sorted by citations
Items 801–877 of 877
Banerjee, M., Malhotra, B., & Pal, R. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01373-x
“…(VOYAGER PAD) trial have demonstrated that compared to aspirin alone, low-dose rivaroxaban and aspirin significantly improve major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) [1–3].”
Can Rivaroxaban Improve Claudication Symptoms? A Promise Never Made
de Mestral, C. (2024) · NEJM Evidence · doi:10.1056/evide2400262
Fowler, X. P., Mehta, K. S., Eid, M. A., Gladders, B. H., Kearing, S. A., Moore, K. O., Creager, M. A., Austin, A. M., Feinberg, M. W., Bonaca, M. P., et al. (2024) · Vascular Medicine · doi:10.1177/1358863x241262330 · Cited by 1
“38,39 Fourth, our assessment of mortality associated with a cardiovascular event likely underestimates the true number of patients who experienced cardiovascular mortality.”
Sander, D. (2024) · Gefässchirurgie · doi:10.1007/s00772-024-01146-0
Efficacy and Safety of Rivaroxaban in the Treatment of Carotid Artery Disease: A Systematic ReviewPreprint
Bandara, H. M. M. P., Hannibal, G. D., & Liyanage, P. (2024) · Research Square · doi:10.21203/rs.3.rs-5290576/v1
Schulze-Bauer, H., Staudacher, M., Steiner, S., & Schlager, O. (2024) · Herz · doi:10.1007/s00059-024-05286-7
Su, S., Huang, Y., & Wei, J. C. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2024.11.352
Optimal Medical Therapy in Peripheral Artery Disease
Bae, J. Y., & Altin, E. S. (2024) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2024.11.002 · Cited by 1
Self-citationStubblefield, W. B., Sullivan, A. E., Cahill, K. N., Amin, T., Boutaud, O. G., Zagol-Ikapitte, I. A., Su, Y. R., Flaherty, D. K., Matlock, B. K., Berger, J. S., et al. (2025) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2025.100197
“25,26 Although the anticoagulant effects of factor Xa inhibition are well-established, rivaroxaban also exhibits an antiplatelet effect by reducing factor Xa agonism of PAR-1.”
Zeymer, U., Bauersachs, R. M., Dagkonakis, N., Debus, E. S., Herold, J., Anand, S. S., Fox, K. A. A., Aboyans, V., & Rauch‐Kröhnert, U. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02603-w
Self-citationAl-Qudah, A. M., Elangovan, C., Sidebottom, C. T., & Krishnaiah, B. (2024) · Journal of Stroke Medicine · doi:10.1177/25166085251320430
“85,86 Where Are We Going?”
Jahn, J. (2025) · Gefässchirurgie · doi:10.1007/s00772-025-01198-w
Mühlbauer, B., & Wille, H. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_9 · Cited by 1
Kola, B. P., Yadav, A. K., Keshava, S. N., Pant, R., Gorsi, U., Warawdekar, G., Sheorain, V., Bansal, N. O., Choudhury, S. R., Halbe, S., et al. (2025) · Journal of Clinical Interventional Radiology ISVIR · doi:10.1055/s-0045-1808058
Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia
Holder, T. A., & Gray, B. H. (2025) · Advances in Surgery · doi:10.1016/j.yasu.2025.04.002
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01323-z
Antithrombotische Therapie bei polyvaskulärer Atherosklerose
Espinola–Klein, C. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2359-4422
“Eine Subgruppen-analyse, an der 7470 Patienten mit peripherer Athero-sklerose (pAVK oder Karotisstenose) teilnahmen, zeigte eine signifikante Reduktion sowohl der MACE-Ereignisse um 28% als auch der MALE-Ereignisse um 46% [25].”
Mureddu, G. F., Rosato, S., D’Errigo, P., Faggiano, P. M., Ciccarelli, P., Badoni, G., Ambrosetti, M., Fattirolli, F., & Baglìo, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124158
Self-citationOral Anticoagulant Management for Peripheral Vascular Disease
Mulaney, B., & Dua, A. (2025) · Advances in Surgery · doi:10.1016/j.yasu.2025.05.003
Xue, S., Wang, X., Lu, T., Pu, H., Peng, Z., Lu, X., & Ye, K. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347174
Peripheral Arterial Disease: What You Need to Know
Bernatchez, J., Fortin, W., Boisvert, A., Douville, Y., Mao, Y. Q., Philippe, É., Côté, F., Langis, P., Béland, M., Zhang, Z., et al. (2025) · Springer eBooks · doi:10.1007/978-3-031-85504-7_3
Novel Interventions to Improve Adherence to Guideline-Directed Medical Therapy in Claudicants
Shi, R., Bulatao, N., & Tanious, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155309 · Cited by 1
“No differences were seen in the rivaroxaban alone group compared with the aspirin alone group [19].”
Murdolo, G., Gaggia, F., Bianchini, E., Monami, M., Miranda, C., Monge, L., Uccioli, L., Gargiulo, M., Scatena, A., Scevola, G., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02562-8
“A subsequent sub-analysis of the PAD cohort (N = 7470) [23] focused primarily on patients with “symptomatic” LE-PAD (N = 4129) [30].”
InfluentialKomarov, A. L., Krivosheeva, E. N., Панченко, Е. П., Yarovaya, E. B., Balakhonova, T. V., Евгеньевна, В. Э., Khakimova, M. B., Погорелова, О. А., & Chernyshenko, E. G. (2025) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2025-4346
Chen, Y., Li, M., & Minglong, C. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.07.008
Wahlgren, C. (2025) · doi:10.1002/9781394223152.ch25
Self-citationBiomarker Analysis from the Compass Claudication Study – Rivaroxaban for Intermittent Claudication
Britto, K. F., Caffaro, R. A., Volpiani, G. G., Portugal, M. F. C., Neves, S., Paganotti, A., Pereira, F. M., Agati, L. B., Ribeiro, C. M., da Silva, V. S., et al. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251372934
Self-citationPharmacologic Therapy to Improve Functional and Limb Outcomes
Raja, A., & Secemsky, E. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-02460-2_9
Matějka, J., Motovska, Z. J., Hlinomaz, O., Kala, P., Hromádka, M., Varvařovský, I., Dušek, J., Jarkovský, J., Rokyta, R., Mrózek, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24372-2
“…hoc analyses of PAD patients enrolled in the PLATO (The Study of Platelet Inhibition and Patient Outcomes) and COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trials showed a reduction in ischaemic endpoints consistent with the overall results of these studies 15,16 .”
Self-citationRivaroxaban and Carotid Plaque Stabilisation: The Promise that Awaits Proof
Moulakakis, K. G., & Mylonas, S. (2025) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2025.10.065
The contemporary role for carotid revascularization in older patients
John, E. S., Stone, D. H., Stillman, D. R., Scully, R. E., & Columbo, J. A. (2025) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2025.11.001
高, 慧. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.46480
Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK)
Dörr, G. (2025) · Geriatrie up2date · doi:10.1055/a-2724-2131
Chan, Y., Lee, H.-F., Li, P.-R., Liu, J.-R., Chao, T.-F., Wu, L.-S., Chang, S.-H., Yeh, Y., Kuo, C.-T., See, L.-C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12299117
Chan, Y., Lee, H.-F., Li, P.-R., Liu, J.-R., Chao, T.-F., Wu, L.-S., Chang, S.-H., Yeh, Y., Kuo, C.-T., See, L.-C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12299126
Wong, K. H. F., Bosanquet, D. C., Ambler, G. K., Qureshi, M. I., Hinchliffe, R. J., & Twine, C. P. (2019) · Figshare · doi:10.6084/m9.figshare.10297451
Chan, Y., Lee, H.-F., Li, P.-R., Liu, J.-R., Chao, T.-F., Wu, L.-S., Chang, S.-H., Yeh, Y., Kuo, C.-T., See, L.-C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12299132
Asymptomatische periphere arterielle Verschlusskrankheit
Stella, J. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_67
Chronisch kritische Extremitätenischämie
Malyar, N. M., & Engelbertz, C. M. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_69
Pradhan, A. K., Bhandari, M., & Agrawala, R. (2025) · International Journal of Angiology · doi:10.1055/a-2755-1789
Rittig, K., Adili, F., Zähringer, M., Malyar, N. M., Rother, U., Balletshofer, B. M., Qiu, H. J., Reimer, P., & Lawall, H. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2593-4467
Rittig, K., Adili, F., Zähringer, M., Malyar, N. M., Rother, U., Balletshofer, B. M., Qiu, H. J., Reimer, P., Lawall, H., (DDG), D. D. G., et al. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01427-0
“In einigen Studien war eine intensivierte Blutdrucktherapie mit einer niedrigen kardiovaskulären Ereignis-rate assoziiert [15, 16].”
Blinc, A., Boc, V., & Schaefer, C. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_25
Isiadinso, I., Waheed, N., & Wenger, N. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00018-5
Mühlbauer, B. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_9
Peripheral Artery Disease in Persons With Type 2 Diabetes
Aday, A. W., & Beckman, J. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00022-7
Marques-Vieira, M., Garrido-Antunes, C., Pereira-Neves, A. H., Gamas, L., Brandão-Silva, J., Marreiros, A., Ribeiro, H., D’Oria, M., & Rocha-Neves, J. P. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.02.046
Shammas, N. W. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.009
Self-citationClinical Akrasia: The Evidence–Action Gap in Peripheral Artery Disease
Halboni, A., & Aronow, H. D. (2026) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.126.016677
Salle, L., Aboyans, V., Vogtländer, K., Debus, E. S., Welsh, R. C., Zeymer, U., Henn, C., & Fox, K. A. A. (2026) · Vascular Medicine · doi:10.1177/1358863x261419733
Self-citationOliveira, J. R. C. D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014177
Morodomi, Y., Yoshino, S., Morisaki, K., Kamikubo, Y., Inoue, R., Fujioka, Y., Inoue, K., Kanaji, S., Kanaji, T., Ishimoto, K., et al. (2026) · Thrombosis Update · doi:10.1016/j.tru.2026.100235 · Cited by 1
Peripheral Artery Disease Treatment: Scoping Review with ☸SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsarafa4dc087
Asymptomatic Carotid Stenosis: Scoping Review with ☸SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara427b99fa
Oletu, H., Irivbogbe, O. A., Barry, N. G., & Akhtar, Y. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105399
“4 Within this framework, the observed associations across mortality and limb outcomes in the present analysis extend prior evidence by examining a population enriched for PAD, where limb events are central to prognosis and are incompletely addressed by existing therapies.”
Chen, L., & Zhang, B. (2026) · Vascular Research · doi:10.15302/vr.2025.0006
Thanigaimani, S., Sun, D., Choy, O. S., Tian, K., & Golledge, J. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.03.060
Chen*+, Z., Yuan*+, K., & Wan, C. (2026) · Tobacco Induced Diseases · doi:10.18332/tid/219768
Wang, X., Zhu, F., Huang, Y., Liu, D., & Xu, L. (2026) · Research Square · doi:10.21203/rs.3.rs-9449777/v1
Bozzani, A., Gallo, E., Salzillo, I., Arici, V., Rossini, R., Rota, M., & Visciglia, E. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001353
Analysis of dual pathway inhibition prescription after percutaneous vascular intervention
Jarosinski, M. C., Lowenkamp, M. N., Madigan, M. C., Reitz, K. M., Chaer, R. A., & Sridharan, N. D. (2026) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2026.100472
Hiruma, Y., Watanabe, A., Aikawa, T., Iwagami, M., Slipczuk, L. N., Wiley, J., Briasoulis, Α., Secemsky, E. A., Laham, R. J., & Kuno, T. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047301
Kim, T. O., Han, S., Ryu, J., Lee, J.-B., Suh, C. H., Wee, S.-B., Kang, S., Moon, D. H., Lee, C. W., Gwon, J. G., et al. (2026) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeag176
Galassi, L., Facchinetti, F., & Ravini, M. L. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.06.049
Shahzaib, M., Roshaan, M., Ali, M. K. B., Hussain, S. I., Khan, N. A., Haiy, A. U., Hamzah, K. A., Shahryar, M., Shahzad, E., Afzal, N., et al. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.06.047
Arif, M., Hidayanti, I., & Haji, S. A. (2026) · EKOMA Jurnal Ekonomi Manajemen Akuntansi · doi:10.56799/ekoma.v5i5.16055
Rittig, K., Adili, F., Zähringer, M., Malyar, N. M., Rother, U., Balletshofer, B. M., Qiu, H. J., Reimer, P., & Lawall, H. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-4074
Kwun, J.-S., Yoon, C., Jeon, K., Cho, H.-W., Park, J. J., Kang, S., Lee, W., Suh, J., Youn, T., Kang, H., et al. (2026) · Trials · doi:10.1186/s13063-026-09899-7
“Furthermore, dual pathway inhibition by combining low-dose rivaroxaban with aspirin (DPI) in stable atherosclerotic patients has shown superiority in reducing mortality and preventing MI and stroke compared to aspirin alone [15, 16].”
Self-citationLee, J.-Y., Jang, J., & Oh, C. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0070
Baker, D., & Benaragama, K. S. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.07.067
Chemical design of diagnostic and therapeutic nanoplatforms for cerebrovascular diseases
Nan, J., Chen, Y., Xia, C., Jiang, W., Cui, Z., Zhang, J., Li, Y., Xia, L., Chen, Y., & Zhang, J. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218425
Self-citationPark, J. (2026) · Family Medicine and Community Health · doi:10.1136/fmch-2026-004259
“24 Both current European and American guidelines identify this combination as a reasonable option in selected patients at high ischaemic and acceptable bleeding risk.”
CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia
Hamady, M., Wolf, F., Rekabi, A. A., Katsanos, K. H., Perkov, D., & Ruffino, M. A. (2026) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-026-04622-0
Miceli, G., Basso, M. G., Cuffaro, M., Marchese, A., & Tuttolomondo, A. (2026) · Medicina · doi:10.3390/medicina62101905
“Dual-pathway inhibition with low-dose rivaroxaban and aspirin provides additional cardiovascular and limb protection in appropriately selected patients at elevated ischemic risk, including those with previous lower-extremity revascularization, provided that bleeding risk is not prohibitive [39].”
InfluentialАнтитромбоцитарна терапія в лікуванні атеросклеротичних серцево-судинних захворювань
Skybchyk, V. А. (2026) · Український медичний часопис · doi:10.32471/umj.1680-3051.281099
Chiang, L.-Y., Chu, Y.-R., Kung, P., Chen, C.-P., & Tsai, W. (2026) · The Journal of Arthroplasty · doi:10.1016/j.arth.2026.09.055
Burlacu, A., Geman, O., & Brinza, C. (2026) · Medicina · doi:10.3390/medicina62112047
Metadata
- Authors
- Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., Maggioni, A. P., Lewis, B. S., Störk, S., Zhu, J., Lopez-Jaramillo, P., O'Donnell, M., Commerford, P. J., Vinereanu, D., Pogosova, N., Ryden, L., Fox, K. A. A., Bhatt, D. L., Misselwitz, F., Varigos, J. D., Vanassche, T., Avezum, A. A., Chen, E., Branch, K., Leong, D. P., Bangdiwala, S. I., Hart, R. G., Yusuf, S., SALA, J., CARTASEGNA, L., VICO, M., HOMINAL, M. A., HASBANI, E., CACCAVO, A., ZAIDMAN, C., VOGEL, D., HRABAR, A., SCHYGIEL, P. O., CUNEO, C., LUQUEZ, H., MACKINNON, I. J., AHUAD GUERRERO, R. A., COSTABEL, J. P., BARTOLACCI, I. P., MONTANA, O., BARBIERI, M., GOMEZ VILAMAJO, O., GARCIA DURAN, R. O., SCHIAVI, L. B., GARRIDO, M., INGARAMO, A., BORDONAVA, A. P., PELAGAGGE, M. J., NOVARETTO, L., ALBISU DI GENNERO, J. P., IBANEZ SAGGIA, L. M., ALVAREZ, M., VITA, N. A., MACIN, S. M., DRAN, R. D., CARDONA, M., GUZMAN, L., SARJANOVICH, R. J., CUADRADO, J., NANI, S., LITVAK BRUNO, M. R., CHACON, C., MAFFEI, L. E., GRINFELD, D., VENSENTINI, N., MAJUL, C. R., LUCIARDI, H. L., GONZALEZ COLASO, P. D. C., FERRE PACORA, F. A., VAN DEN HEUVEL, P., VERHAMME, P., ECTOR, B., DEBONNAIRE, P., VAN DE BORNE, P., LEROY, J., SCHROE, H., VRANCKX, P., ELEGEERT, I., HOFFER, E., DUJARDIN, K., INDIO DO BRASIL, C., PRECOMA, D., ABRANTES, J. A., MANENTI, E., REIS, G., SARAIVA, J., MAIA, L., HERNANDES, M., ROSSI, P., ROSSI DOS SANTOS, F., ZIMMERMANN, S. L., RECH, R., ABIB JR, E., LEAES, P., BOTELHO, R., DUTRA, O., SOUZA, W., BRAILE, M., IZUKAWA, N., NICOLAU, J. C., TANAJURA, L. F., SERRANO JUNIOR, C. V., MINELLI, C., NASI, L. A., OLIVEIRA, L., DE CARVALHO CANTARELLI, M. J., TYTUS, R., PANDEY, S., LONN, E., CHA, J., VIZEL, S., BABAPULLE, M., LAMY, A., SAUNDERS, K., BERLINGIERI, J., KIAII, B., BHARGAVA, R., MEHTA, P., HILL, L., FELL, D., LAM, A., AL-QOOFI, F., BROWN, C., PETRELLA, R., RICCI, J. A., GLANZ, A., NOISEUX, N., BAINEY, K., MERALI, F., HEFFERNAN, M., DELLA SIEGA, A., DAGENAIS, G. R., DAGENAIS, F., BRULOTTE, S., NGUYEN, M., HARTLEIB, M., GUZMAN, R., BOURGEOIS, R., RUPKA, D., KHAYKIN, Y., GOSSELIN, G., HUYNH, T., PILON, C., CAMPEAU, J., PICHETTE, F., DIAZ, A., JOHNSTON, J., SHUKLE, P., HIRSCH, G., RHEAULT, P., CZARNECKI, W., ROY, A., NAWAZ, S., FREMES, S., SHUKLA, D., JANO, G., COBOS, J. L., CORBALAN, R., MEDINA, M., NAHUELPAN, L., RAFFO, C., PEREZ, L., POTTHOFF, S., STOCKINS, B., SEPULVEDA, P., PINCETTI, C., VEJAR, M., TIAN, H., WU, X., KE, Y., JIA, K., YIN, P., WANG, Z., YU, L., WU, S., WU, Z., LIU, S. W., BAI, X. J., ZHENG, Y., YANG, P., YANG, Y. M., ZHANG, J., GE, J., CHEN, X. P., LI, J., HU, T. H., ZHANG, R., ZHENG, Z., CHEN, X., TAO, L., LI, J., HUANG, W., FU, G., LI, C., DONG, Y., WANG, C., ZHOU, X., KONG, Y., SOTOMAYOR, A., ACCINI MENDOZA, J. L., CASTILLO, H., URINA, M., AROCA, G., PEREZ, M., MOLINA DE SALAZAR, D. I., SANCHEZ VALLEJO, G., FERNANDO, M. J., GARCIA, H., GARCIA, L. H., ARCOS, E., GOMEZ, J., CUERVO MILLAN, F., TRUJILLO DADA, F. A., VESGA, B., MORENO SILGADO, G. A., ZIDKOVA, E., LUBANDA, J.-C., KALETOVA, M., KRYZA, R., MARCINEK, G., RICHTER, M., SPINAR, J., MATUSKA, J., TESAK, M., MOTOVSKA, Z., BRANNY, M., MALY, J., MALY, M., WIENDL, M., FOLTYNOVA CAISOVA, L., SLABY, J., VOJTISEK, P., PIRK, J., SPINAROVA, L., BENESOVA, M., CANADYOVA, J., HOMZA, M., FLORIAN, J., POLASEK, R., COUFAL, Z., SKALNIKOVA, V., BRAT, R., BRTKO, M., JANSKY, P., LINDNER, J., MARCIAN, P., STRAKA, Z., TRETINA, M., DUARTE, Y. C., POW CHON LONG, F., SANCHEZ, M., LOPEZ, J., PERUGACHI, C., MARMOL, R., TRUJILLO, F., TERAN, P., TUOMILEHTO, J., TUOMILEHTO, H., TUOMINEN, M.-L., TUOMILEHTO, H., KANTOLA, I., STEG, G., ABOYANS, V., LECLERCQ, F., FERRARI, E., BOCCARA, F., MESSAS, E., MISMETTI, P., SEVESTRE, M. A., CAYLA, G., MOTREFF, P., STOERK, S., DUENGEN, H.-D., STELLBRINK, C., GUEROCAK, O., KADEL, C., BRAUN-DULLAEUS, R., JESERICH, M., OPITZ, C., VOEHRINGER, H.-F., APPEL, K.-F., WINKELMANN, B., DORSEL, T., NIKOL, S., DARIUS, H., RANFT, J., SCHELLONG, S., JUNGMAIR, W., DAVIERWALA, P., VORPAHL, M., BAJNOK, L., LASZLO, Z., NOORI, E., VERESS, G., VERTES, A., ZSARY, A., KIS, E., KORANYI, L., BAKAI, J., BODA, Z., POOR, F., JARAI, Z., KEMENY, V., BARTON, J., MCADAM, B., MURPHY, A., CREAN, P., MAHON, N., CURTIN, R., MACNEILL, B., DINNEEN, S., HALABI, M., ZIMLICHMAN, R., ZELTSER, D., TURGEMAN, Y., KLAINMAN, E., LEWIS, B., KATZ, A., ATAR, S., ZIMLICHMAN, R., NIKOLSKY, E., BOSI, S., NALDI, M., FAGGIANO, P., ROBBA, D., MOS, L., SINAGRA, G., COSMI, F., OLTRONA VISCONTI, L., CARMINE, D. M., DI PASQUALE, G., DI BIASE, M., MANDORLA, S., BERNARDINANGELI, M., PICCINNI, G. C., GULIZIA, M. M., GALVANI, M., VENTURI, F., MOROCUTTI, G., BALDIN, M. G., OLIVIERI, C., PERNA, G. P., CIRRINCIONE, V., KANNO, T., DAIDA, H., OZAKI, Y., MIYAMOTO, N., HIGASHIUE, S., DOMAE, H., HOSOKAWA, S., KOBAYASHI, H., KURAMOCHI, T., FUJII, K., MIZUTOMI, K., SAKU, K., KIMURA, K., HIGUCHI, Y., ABE, M., OKUDA, H., NODA, T., MITA, T., HIRAYAMA, A., ONAKA, H., INOKO, M., HIROKAMI, M., OKUBO, M., AKATSUKA, Y., IMAMAKI, M., KAMIYA, H., MANITA, M., HIMI, T., UENO, H., HISAMATSU, Y., AKO, J., NISHINO, Y., KAWAKAMI, H., YAMADA, Y., KORETSUNE, Y., YAMADA, T., YOSHIDA, T., SHIMOMURA, H., KINOSHITA, N., TAKAHASHI, A., YUSOFF, K., WAN AHMAD, W. A., ABU HASSAN, M. R., KASIM, S., ABDUL RAHIM, A. A., MOHD ZAMRIN, D., MACHIDA, M., HIGASHINO, Y., UTSU, N., NAKANO, A., NAKAMURA, S., HASHIMOTO, T., ANDO, K., SAKAMOTO, T., PRINS, F. J., LOK, D., MILHOUS, J. G.-J., VIERGEVER, E., WILLEMS, F., SWART, H., ALINGS, M., BREEDVELD, R., DE VRIES, K.-J., VAN DER BORGH, R., OEI, F., ZOET-NUGTEREN, S., KRAGTEN, H., HERRMAN, J. P., VAN BERGEN, P., GOSSELINK, M., HOEKSTRA, E., ZEGERS, E., RONNER, E., DEN HARTOG, F., BARTELS, G., NIEROP, P., VAN DER ZWAAN, C., VAN ECK, J., VAN GORSELEN, E., GROENEMEIJER, B., HOOGSLAG, P., DE GROOT, M. R., LOYOLA, A., SULIT, D. J., REY, N., ABOLA, M. T., MORALES, D., PALOMARES, E., ABAT, M. E., ROGELIO, G., CHUA, P., DEL PILAR, J. C., ALCARAZ, J. D., EBO, G., TIRADOR, L., CRUZ, J., ANONUEVO, J., PITARGUE, A., JANION, M., GUZIK, T., GAJOS, G., ZABOWKA, M., RYNKIEWICZ, A., BRONCEL, M., SZUBA, A., CZARNECKA, D., MAGA, P., STRAZHESKO, I., VASYUK, Y., SIZOVA, Z., POZDNYAKOV, Y., BARBARASH, O., VOEVODA, M., POPONINA, T., REPIN, A., OSIPOVA, I., EFREMUSHKINA, A., NOVIKOVA, N., AVERKOV, O., ZATEYSHCHIKOV, D., VERTKIN, A., AUSHEVA, A., COMMERFORD, P., SEEDAT, S., VAN ZYL, L., ENGELBRECHT, J., MAKOTOKO, E. M., PRETORIUS, C. E., MOHAMED, Z., HORAK, A., MABIN, T., KLUG, E., BAE, J.-H., KIM, C., KIM, C.-J., KIM, D.-S., KIM, Y. J., JOO, S., HA, J.-W., PARK, C. S., KIM, J. Y., KIM, Y.-K., JARNERT, C., MOOE, T., DELLBORG, M., TORSTENSSON, I., ALBERTSSON, P., JOHANSSON, L., AL-KHALILI, F., ALMROTH, H., ANDERSSON, T., PANTEV, E., TENGMARK, B.-O., LIU, B., RASMANIS, G., WAHLGREN, C.-M., MOCCETTI, T., PARKHOMENKO, A., TSELUYKO, V., VOLKOV, V., KOVAL, O., KONONENKO, L., PROKHOROV, O., VDOVYCHENKO, V., BAZYLEVYCH, A., RUDENKO, L., VIZIR, V., KARPENKO, O., MALYNOVSKY, Y., KOVAL, V., STOROZHUK, B., COTTON, J., VENKATARAMAN, A., MORIARTY, A., CONNOLLY, D., DAVEY, P., SENIOR, R., BIRDI, I., CALVERT, J., DONNELLY, P., TREVELYAN, J., CARTER, J., PEACE, A., AUSTIN, D., KUKREJA, N., HILTON, T., SRIVASTAVA, S., WALSH, R., FIELDS, R., HAKAS, J., PORTNAY, E., GOGIA, H., SALACATA, A., HUNTER, J. J., BACHARACH, J. M., SHAMMAS, N., SURESH, D., SCHNEIDER, R., GURBEL, P., BANERJEE, S., GRENA, P., BEDWELL, N., SLOAN, S., LUPOVITCH, S., SONI, A., GIBSON, K., SANGRIGOLI, R., MEHTA, R., I-HSUAN TSAI, P., GILLESPIE, E., DEMPSEY, S., HAMROFF, G., BLACK, R., LADER, E., KOSTIS, J. B., BITTNER, V., MCGUINN, W., BRANCH, K., MALHOTRA, V., MICHAELSON, S., VACANTE, M., MCCORMICK, M., ARIMIE, R., CAMP, A., DAGHER, G., KOSHY, N. M., THEW, S., COSTELLO, F., HEIMAN, M., CHILTON, R., MORAN, M., ADLER, F., COMEROTA, A., SEIWERT, A., FRENCH, W., SEROTA, H., HARRISON, R., BAKAEEN, F., OMER, S., CHANDRA, L., WHELAN, A., BOYLE, A., ROBERTS-THOMSON, P., ROGERS, J., CARROLL, P., COLQUHOUN, D., SHAW, J., BLOMBERY, P., AMERENA, J., HII, C., ROYSE, A., SINGH, B., SELVANAYAGAM, J., JANSEN, S., LO, W., HAMMETT, C., POULTER, R., NARASIMHAN, S., WIGGERS, H., NIELSEN, H., GISLASON, G., KOBER, L., HOULIND, K., BOENELYKKE SOERENSEN, V., DIXEN, U., REFSGAARD, J., ZEUTHEN, E., SOEGAARD, P., HRANAI, M., GASPAR, L., PELLA, D., HATALOVA, K., DROZDAKOVA, E., COMAN, I., DIMULESCU, D., VINEREANU, D., CINTEZA, M., SINESCU, C., ARSENESCU, C., BENEDEK, I., BOBESCU, E., DOBREANU, D., GAITA, D., IANCU, A., ILIESIU, A., LIGHEZAN, D., PETRESCU, L., PIRVU, O., TEODORESCU, I., TESLOIANU, D., VINTILA, M. M., & CHIONCEL, O.
- Affiliations
- Population Health Research Institute (CA)
- Charles University (CZ)
- Thrombosis Research Institute (GB)
- Semmelweis University (HU)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- University of Würzburg (DE)
- Fu Wai Hospital (CN)
- Ollscoil na Gaillimhe – University of Galway (IE)
- University of Edinburgh (GB)
- Brigham and Women's Hospital (US)
- Bayer (Germany) (DE)
- Monash University (AU)
- KU Leuven (BE)
- Bayer (United States) (US)
- Universidad Autónoma de Madrid (ES)
- Estudios Clínicos Latinoamérica (AR)
- Hamilton General Hospital (CA)
- McMaster University (CA)
- University of Washington (US)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Paris Cardiovascular Research Center (FR)
- University of Cape Town (ZA)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Werkgroep Cardiologische centra Nederland (NL)
- University of Debrecen (HU)
- University of Trieste (IT)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Hôpital Universitaire Dupuytren (FR)
- Istituto Cardiocentro Ticino (CH)
- Danylo Halytsky Lviv National Medical University (UA)
- Foscal Hospital (CO)
- National Research Center for Preventive Medicine (RU)
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul de Urgenţă pentru Boli Cardiovasculare "Prof.Dr. C.C. Iliescu" (RO)
- Corresponding author
- Anand, Sonia S
- ORCID
- Anand, Sonia S
- Bosch, Jackie
- Eikelboom, John W
- Connolly, Stuart J
- Kakkar, Ajay K
- Keltai, Katalin
- Maggioni, Aldo P
- Störk, Stefan
- Zhu, Jun
- O'Donnell, Martin
- Fox, Keith A A
- Bhatt, Deepak L
- Misselwitz, Frank
- Vanassche, Thomas
- Leong, Darryl P
- Bangdiwala, Shrikant I
- Hart, Robert G
- Yusuf, Salim
- SCHYGIEL, PABLO OMAR
- COSTABEL, JUAN PABLO
- MACIN, STELLA MARIS
- GRINFELD, DIEGO
- VERHAMME, PETER
- DEBONNAIRE, PHILIPPE
- VRANCKX, PASCAL
- ELEGEERT, IVAN
- HOFFER, ETIENNE
- MANENTI, EULER
- REIS, GILMAR
- HERNANDES, MAURO
- TANAJURA, LUIZ FERNANDO
- TYTUS, RICHARD
- LONN, EVA
- LAMY, ANDRE
- NOISEUX, NICOLAS
- BAINEY, KEVIN
- DAGENAIS, GILLES R
- NGUYEN, MICHEL
- GUZMAN, RANDOLPH
- KHAYKIN, YAARIV
- GOSSELIN, GILBERT
- HUYNH, THAO
- ROY, ANNIE
- JIA, KAIYING
- WU, SHULIN
- ZHANG, JIWEI
- GE, JUNBO
- FU, GUOSHENG
- VESGA, BORIS
- LUBANDA, JEAN-CLAUDE
- MOTOVSKA, ZUZANA
- BRANNY, MARIAN
- HOMZA, MIROSLAV
- BRTKO, MIROSLAV
- DUARTE, YAN CARLOS
- SANCHEZ, MAYRA
- TUOMILEHTO, JAAKKO
- KANTOLA, ILKKA
- LECLERCQ, FLORENCE
- BOCCARA, FRANCK
- MESSAS, EMMANUEL
- SEVESTRE, MARIE ANTOINETTE
- CAYLA, GUILLAUME
- MOTREFF, PASCAL
- STELLBRINK, CHRISTOPH
- OPITZ, CHRISTIAN
- NIKOL, SIGRID
- SCHELLONG, SEBASTIAN
- DAVIERWALA, PIROZE
- VORPAHL, MARC
- KORANYI, LASZLO
- MURPHY, ANDREW
- MAHON, NIALL
- HALABI, MAJDI
- ZELTSER, DAVID
- KATZ, AMOS
- ATAR, SHAUL
- FAGGIANO, POMPILIO
- ROBBA, DEBORA
- MOS, LUCIO
- SINAGRA, GIANFRANCO
- GULIZIA, MICHELE MASSIMO
- GALVANI, MARCELLO
- PERNA, GIAN PIERO
- OZAKI, YUKIO
- HIGASHIUE, SHINICHI
- HOSOKAWA, SHINOBU
- FUJII, KENSHI
- KIMURA, KAZUO
- HIGUCHI, YOSHIHARU
- NODA, TOSHIYUKI
- HIRAYAMA, ATSUSHI
- INOKO, MORIAKI
- MANITA, MAMORU
- AKO, JUNYA
- YOSHIDA, TETSURO
- SHIMOMURA, HIDEKI
- KINOSHITA, NORIYUKI
- TAKAHASHI, AKIHIKO
- YUSOFF, KHALID
- KASIM, SAZZLI
- NAKANO, AKIHIKO
- NAKAMURA, SHIGERU
- SAKAMOTO, TOMOHIRO
- RONNER, EELKO
- BARTELS, GERARD
- ABOLA, MARIA TERESA
- ABAT, MARC EVANS
- JANION, MARIANNA
- GUZIK, TOMASZ
- GAJOS, GRZEGORZ
- RYNKIEWICZ, ANDRZEJ
- BRONCEL, MARLENA
- SZUBA, ANDRZEJ
- CZARNECKA, DANUTA
- SIZOVA, ZHANNA
- VOEVODA, MIKHAIL
- REPIN, ALEXEY
- EFREMUSHKINA, ANNA
- ZATEYSHCHIKOV, DMITRY
- BAE, JANG-HO
- HA, JONG-WON
- MOOE, THOMAS
- DELLBORG, MIKAEL
- ALBERTSSON, PER
- WAHLGREN, CARL-MAGNUS
- MOCCETTI, TIZIANO
- PARKHOMENKO, ALEXANDER
- TSELUYKO, VIRA
- KOVAL, OLENA
- BAZYLEVYCH, ANDRIY
- KARPENKO, OLEKSANDR
- MALYNOVSKY, YAROSLAV
- COTTON, JAMES
- CONNOLLY, DEREK
- DAVEY, PATRICK
- SENIOR, ROXY
- PEACE, AARON
- AUSTIN, DAVID
- SRIVASTAVA, SUNNY
- SHAMMAS, NICOLAS
- GURBEL, PAUL
- BANERJEE, SUBHASH
- MEHTA, RAJENDRA
- GILLESPIE, EVE
- HAMROFF, GLENN
- LADER, ELLIS
- KOSTIS, JOHN B.
- BITTNER, VERA
- CHILTON, ROBERT
- COMEROTA, ANTHONY
- BAKAEEN, FAISAL
- AMERENA, JOHN
- ROYSE, ALISTAIR
- SELVANAYAGAM, JOSEPH
- JANSEN, SHIRLEY
- HAMMETT, CHRISTOPHER
- POULTER, ROHAN
- NARASIMHAN, SESHASAYEE
- GISLASON, GUNNAR
- HOULIND, KIM
- DIXEN, ULRIK
- REFSGAARD, JENS
- PELLA, DANIEL
- SINESCU, CRINA
- BENEDEK, IMRE
- BOBESCU, ELENA
- DOBREANU, DAN
- IANCU, ADRIAN
- LIGHEZAN, DANIEL
- PETRESCU, LUCIAN
- TESLOIANU, DAN
- CHIONCEL, OVIDIU
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 391
- Issue
- 10117
- Pages
- 219-229
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4229536675
- Semantic Scholar
- af705d340539758c05004e20b5429bd9700e2fc2
- Cited by
- 879
- References
- 30
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 74 · 2023: 99 · 2022: 109 · 2021: 139 · 2020: 152 · 2019: 112 · 2018: 74
- FWCI
- 72.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion)
- HAL (submittedVersion)
- ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (submittedVersion, cc-by-nc-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- rivaroxaban, aspirin, peripheral arterial disease, carotid artery disease, coronary artery disease, major adverse limb events, major amputation, cardiovascular mortality, myocardial infarction, stroke, antiplatelet therapy, direct oral anticoagulants, ankle-brachial index, intermittent claudication, asymptomatic carotid stenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review